Weekly Isotretinoin vs Tetracycline for Moderate Acne - Trial NCT06225570
Access comprehensive clinical trial information for NCT06225570 through Pure Global AI's free database. This Phase 1 trial is sponsored by Medical University of South Carolina and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Medical University of South Carolina
Timeline & Enrollment
Phase 1
Feb 01, 2024
Jun 01, 2025
Primary Outcome
Efficacy using Comprehensive Acne Severity Scale
Summary
In the effort to find better treatments for Moderate Acne, which often relies on long-term
 antibiotic use, researchers are exploring alternative options. While Isotretinoin, a Vitamin
 A derivative, is highly effective for severe acne, its side effects limit its use for milder
 cases. A recent study from our institution investigated a new approach: weekly Isotretinoin
 dosing. The results were promising, with acne improvement and no major side effects. This
 suggests that weekly Isotretinoin could be a successful alternative for moderate acne in both
 males and females. To validate these findings, investigators propose a randomized controlled
 trial comparing weekly Isotretinoin to daily Doxycycline over four months. This study could
 confirm the safety and effectiveness of weekly Isotretinoin, as well as shed light on patient
 satisfaction, and long-term results compared to standard antibiotics. This research may offer
 a breakthrough in treating moderate acne while addressing concerns about antibiotic overuse.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06225570
Non-Device Trial